We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells. Derivative 8 was found to have improved antiproliferative activity relative to 1. Fluorescent cell imaging revealed that compound 8 preferentially localises within the lysosome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456774 | PMC |
| http://dx.doi.org/10.1039/d0cc08156f | DOI Listing |
Publication Analysis
Top Keywords
studies deferasirox
4
deferasirox derivatives
4
derivatives potential
4
potential organelle-targeting
4
organelle-targeting traceable
4
traceable anti-cancer
4
anti-cancer therapeutics
4
therapeutics report
4
report strategic
4
strategic functionalization
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!